BioCentury
ARTICLE | Clinical News

Sensitivity of Berry Genomics' early HCC screen exceeds 90%

September 28, 2018 5:27 PM UTC

Berry Genomics Co. Ltd. (SZSE:000710) said its PreCar next-generation sequencing-based liver cancer risk prediction model detected early hepatocellular carcinoma with >90% sensitivity at 95% specificity in a pilot trial. At 99% specificity, the model detected early HCC with 87% sensitivity.

The company is planning additional studies to optimize the model in a program that will recruit more than 10,000 patients at high risk for liver cancer, including more than 5,000 patients with cirrhosis and more than 5,000 patients with HBV infection...

BCIQ Company Profiles

Berry Genomics Co. Ltd.